CRSP Aperçu des actions
CRISPR Therapeutics AG, une société d'édition de gènes, se concentre sur le développement de médicaments à base de gènes pour des maladies humaines graves en utilisant sa plateforme CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) /CRISPR-associated protein 9 (Cas9). Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 1/6 |
| Croissance future | 2/6 |
| Performances passées | 0/6 |
| Santé financière | 6/6 |
| Dividendes | 0/6 |
CRISPR Therapeutics AG Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$47.88 |
| Plus haut sur 52 semaines | US$91.10 |
| Plus bas sur 52 semaines | US$43.42 |
| Bêta | 1.66 |
| 1Variation sur 1 mois | 1.10% |
| Variation sur 3 mois | -2.62% |
| Variation sur 1 an | -31.57% |
| 3Variation sur 3 ans | -39.23% |
| Variation sur 5 ans | -33.18% |
| Évolution depuis l'introduction en bourse | 239.82% |
Nouvelles et mises à jour récentes
Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism
Nov 11Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results
Nov 07
Crispr Therapeutics: Poised For A Major Turnaround
Oct 28CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected
Oct 02Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres
Sep 13Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation
Sep 04Recent updates
Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism
Nov 11Here's What Analysts Are Forecasting For CRISPR Therapeutics AG (NASDAQ:CRSP) After Its Third-Quarter Results
Nov 07Crispr Therapeutics: Poised For A Major Turnaround
Oct 28CRISPR Therapeutics AG (NASDAQ:CRSP) Investors Are Less Pessimistic Than Expected
Oct 02Crispr Therapeutics: Casgevy Now Active Across 35 Treatment Centres
Sep 13Here's Why We're Not At All Concerned With CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Situation
Sep 04Crispr's Casgevy Launch: Promising Start, Uncertain Future
Aug 14A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Aug 09Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential
Aug 07Crispr Therapeutics Remains Expensive, With Slower Casgevy Monetization And Patent Battle
Jul 13Crispr Therapeutics: Beaten Down But Not Broken
Jul 07CRISPR Therapeutics AG's (NASDAQ:CRSP) Share Price Could Signal Some Risk
Jun 18Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)
Jun 10Crispr Therapeutics' Strategic Moves Amidst Gene Therapy Challenges (Rating Upgrade)
Jun 03Shareholders Will Probably Hold Off On Increasing CRISPR Therapeutics AG's (NASDAQ:CRSP) CEO Compensation For The Time Being
May 23Newsflash: CRISPR Therapeutics AG (NASDAQ:CRSP) Analysts Have Been Trimming Their Revenue Forecasts
May 13We're Not Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn
May 10Crispr Therapeutics Q1 Earnings: Casgevy Launch Tip Of Gene Editing Iceberg
May 09Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)
May 03Crispr Therapeutics: Now Is The Time To Buy
Apr 24Calculating The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Apr 16Crispr Therapeutics: CASGEVY Commercial Launch Is Taking Shape
Mar 26There's Reason For Concern Over CRISPR Therapeutics AG's (NASDAQ:CRSP) Massive 26% Price Jump
Feb 22Crispr Therapeutics: Cautiously Optimistic
Feb 22Crispr Therapeutics: Investors Bet Against Casgevy Uptake
Feb 01Crispr Therapeutics: Commercial Validation Is The Next Step
Jan 18Impact Of Gene Therapies And Casgevy On Crispr AG And The Industry
Jan 11CRISPR Therapeutics AG's (NASDAQ:CRSP) Popularity With Investors Is Under Threat From Overpricing
Dec 25CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Nov 02A Look At The Intrinsic Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Oct 05CRISPR Therapeutics AG's (NASDAQ:CRSP) Business Is Yet to Catch Up With Its Share Price
Sep 14We're Not Very Worried About CRISPR Therapeutics' (NASDAQ:CRSP) Cash Burn Rate
Jul 24Calculating The Fair Value Of CRISPR Therapeutics AG (NASDAQ:CRSP)
Jun 28CRISPR Therapeutics (NASDAQ:CRSP) Is In A Good Position To Deliver On Growth Plans
Apr 02CRISPR Therapeutics AG's (NASDAQ:CRSP) Intrinsic Value Is Potentially 34% Above Its Share Price
Mar 06Companies Like CRISPR Therapeutics (NASDAQ:CRSP) Are In A Position To Invest In Growth
Dec 08CRISPR CAR T cell therapy for skin/blood cancer gets FDA regenerative medicine tag
Sep 28Crispr: Elucidating And Forecasting Key Developments
Sep 21Rendement pour les actionnaires
| CRSP | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | 1.3% | 2.5% | 2.2% |
| 1Y | -31.6% | 16.1% | 31.6% |
Rendement vs Industrie: CRSP a sous-performé le secteur US Biotechs qui a rapporté 16.1 % au cours de l'année écoulée.
Rendement vs marché: CRSP a sous-performé le marché US qui a rapporté 31.6 % au cours de l'année écoulée.
Volatilité des prix
| CRSP volatility | |
|---|---|
| CRSP Average Weekly Movement | 6.3% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: CRSP n'a pas connu de volatilité de prix significative au cours des 3 derniers mois.
Volatilité au fil du temps: La volatilité hebdomadaire de CRSP ( 6% ) est restée stable au cours de l'année écoulée.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2013 | 407 | Sam Kulkarni | www.crisprtx.com |
CRISPR Therapeutics AG, une société d'édition de gènes, se concentre sur le développement de médicaments à base de gènes pour des maladies humaines graves en utilisant sa plateforme CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) / CRISPR-associated protein 9 (Cas9). CRISPR/Cas9 est une technologie d'édition de gènes qui permet d'apporter des modifications précises et ciblées à l'ADN génomique. La société dispose d'un portefeuille de programmes thérapeutiques dans plusieurs domaines, notamment les hémoglobinopathies, l'immuno-oncologie et les maladies auto-immunes, in vivo, et le diabète de type 1.
CRISPR Therapeutics AG Résumé des fondamentaux
| CRSP statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$4.09b |
| Bénéfices(TTM) | -US$239.59m |
| Recettes(TTM) | US$202.83m |
20.1x
Ratio P/S-17.1x
Ratio P/ELe site CRSP est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| CRSP compte de résultat (TTM) | |
|---|---|
| Recettes | US$202.83m |
| Coût des recettes | US$463.89m |
| Marge brute | -US$261.06m |
| Autres dépenses | -US$21.47m |
| Les revenus | -US$239.59m |
Derniers bénéfices déclarés
Sep 30, 2024
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -2.81 |
| Marge brute | -128.71% |
| Marge bénéficiaire nette | -118.13% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de CRSP?
Voir les performances historiques et les comparaisons